- Open Access
Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome
© Wang et al; licensee BioMed Central Ltd. 2007
- Received: 30 June 2007
- Accepted: 20 November 2007
- Published: 20 November 2007
Castleman's disease of the pancreas is a very rare condition that may resemble more common disease entities as well as pancreatic cancer.
Here we report the case of a 58-year-old African American male with an incidentally discovered lesion in the head of the pancreas. The specimen from his pancreaticoduodectomy contained a protuberant, encapsulated mass, exhibiting microscopic features most consistent with localized/unicentric Castleman's disease. These included florid follicular hyperplasia with mantle/marginal zone hyperplasia along with focal progressive transformation of germinal centers admixed with involuted germinal centers.
To date, eight cases of Castleman's disease associated with the pancreas have been described in the world literature. We report the first case of unicentric disease situated within the head of the pancreas. In addition, we discuss the diagnostic dilemma Castleman's disease may present to the pancreatic surgeon and review current data on pathogenesis, treatment, and outcome.
- Germinal Center
- African American Male
- Multicentric Disease
- Clonal Rearrangement
- Unicentric Disease
Localized lymphoid hyperplasia of the pancreas is rarely reported and is often indistinguishable from pancreatic neoplasms both clinically or radiographically [1, 2]. Castleman's disease (CD), a morphologically distinct form of lymph node hyperplasia is very rare, and even more infrequent in the pancreas . Currently, there are only eight reported cases in the literature [3–10]. In our case, the lesion within the head of the pancreas was presumed to be a pancreatic carcinoma, and a classical pancreaticoduodenectomy (PD) was performed. Pathological examination instead revealed changes consistent with a localized or unicentric hyaline-vascular (HV) variant of CD within the head of the pancreas. In this communication, we review the diagnosis, pathogenesis, treatment, and outcome for this rare clinical entity.
Historically, CD, also known as angiofollicular lymph node hyperplasia, remains a rare and poorly understood disease characterized by massive growth of lymphoid tissue. CD was first described as a pathological entity in 1954 and later defined by Castleman et al., in 1956 . A variety of terms have been used to describe this disorder, including giant lymph node hyperplasia, lymph node hamartoma, follicular lymophoreticuloma, benign giant lymphoma, angiomatous lymphoid hamartoma, and angiofollicular mediastinal lymph node hyperplasia. Flendrig and Schillings  described two basic histopathological subtypes and one mixed variant which Keller et al.  later designated HV, plasma cell (PC), and hyaline-vascular plasma cell "mixed" types (HV-PC). Categorization of CD into clinically relevant subtypes was proposed by McCarty et al.  and Gaba et al.  into unicentric and multicentric variants, respectively. In general, HV-CD is commonly associated with a localized -asymptomatic mass (76–91%) [15, 16], while PC-CD is usually multicentric and symptomatic in 50% of patients.
Unicentric and multicentric CD differ in their clinical presentation and distribution of adenopathy. In a series from Memorial Sloan-Kettering Cancer Center (MSKCC) , patients with unicentric CD were frequently discovered incidentally with symptoms mostly arising from mass compression. Masses found in unicentric disease were usually centrally located in the abdomen and pelvis (54%) and mediastinum (31%), whereby systemic symptoms, central and peripheral adenopathy, organomegaly, and associated abnormal laboratory values (elevated erythrocyte sedimentation rates [ESR], interleukin-6 [IL-6], anemia and polyclonal gammaglobulinemia) were predominant in the multicentric variant.
Our current understanding of the pathogenesis of CD points to reactive follicular hyperplasia in response to an unknown antigenic stimulus . In the current report, the role of HCV infection (positive serology for anti-HCV) in the pathogenesis of HV-CD is possible. This view has been shared by others. Multicentric PC-CD has been previously reported to be associated with concurrent HCV infection in a child with Klinefelter's syndrome and nonregulated antibody production mimicking systemic lupus erythematosus stabilized by interferon-alpha therapy suggesting an association with HCV . Likewise, a report associating reactive lymphoid hyperplasia representing a pseudo-lymphoma of the liver was detailed in a patient with chronic hepatitis C . Moreover, the potential role of HCV infection in an antigen-driven lymphoproliferative model for the pathogenesis of unrelated lymphoproliferative disease entities including non-Hodgkin's lymphoma, marginal zone B-cell lymphoma, or extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) further supports this hypothesis. Nevertheless, the association of concurrent HCV infection and HV-CD requires further investigation. In addition, other etiologies including chronic low grade inflammation , harmartomatous process [20, 21], immunodeficiency [22–24], and autoimmunity  have all been proposed as possible pathogenic mechanisms. Epstein-Barr virus, Toxoplasma, and Mycobacterium tuberculosis also have been linked to this disorder [13, 25]. Interestingly, lymph nodes from various animal models and patients with CD implicate IL-6 as a causative agent for the commonly observed systemic manifestations [20, 26–29].
The initial challenge in CD remains in establishing the diagnosis. Considerable imprecision exists in distinguishing CD from other lymphoid and non-lymphoproliferative disorders that it may resemble clinically and pathologically . Therefore, in the appropriate clinical setting, the diagnosis of CD must be considered, after investigating and excluding more common causes of lymphadenopathy or associated neoplastic processes. Intra-operatively, distinguishing CD involving the head of the pancreas from pancreatic carcinoma may be problematic and strong suspicion of pancreatic malignancy as in our case may prompt traditional surgical removal. Possible clues for the pancreatic surgeon may include evidence of an encapsulated pancreatic mass that is well-circumscribed, and smooth; an uncommon finding for pancreatic adenocarcinoma. Indeed, the diagnosis ultimately rests on precise pathologic investigation.
Unicentric CD is largely the HV- type. HV-CD typically occurs as an isolated lymph node mass or regional adenopathy. These patients are frequently asymptomatic. From a histopathologic standpoint, "lollipop" follicles; germinal centers surrounded by circumferentially arranged layers ("onion skin") of small lymphocytes interconnected by a prominent vascular stroma are characteristic pathological findings. In this report, our patient had all the classical features of unicentric HV-CD. Conversely, the PC-CD subtype demonstrates continuous sheets of dense plasma cells and a less vascular interfollicular stroma surrounding the germinal centers .
Summary of patients with unicentric Castleman's disease involving the pancreas
Tail of Pancreas
NED (2 Yrs)
NED (1 yr)
Body and Tail
Tail of Pancreas
NED+ (11 mos)
Tail of Pancreas
Head of Pancreas
NED (1 yr)
Additional studies have further clarified the natural history following resection. From a consensus standpoint, surgical resection is the mainstay of treatment for unicentric CD with most reports describing complete resection as being curative. In a recent report from MSKCC , complete resection of unicentric disease was curative for all patients regardless of histologic subtype. Likewise, Keller et al.  retrospectively examined 61 patients with unicentric disease who were treated with surgery over a 20 year period. Their study demonstrated that for patients with unicentric HV-CD, complete resection offered the best chance for cure. In certain cases, if complete resection is not possible, partial resection or observation with long term follow-up may be useful. As reported, radiographic examination (CT or MRI) along with arteriography and embolization has been used to facilitate surgical excision and minimize intraopertative bleeding, which can be profuse [31–34].
A limited number of reports address the response of CD to radiotherapy (2700–4500 cGy) administered to involved sites which has resulted in remission of disease in isolated cases [28, 35–42], but failed in others [13, 15, 43]. Keller et al. , reported on four patients with unicentric-HV disease who were treated with 1800–4300 cGy with no response. Notably, a complete response of the unicentric-HV variant was reported by Sethi et al. , in a patient with systemic symptoms treated with 4000 cGy. However, irradiation was noted to produce a range of favorable responses in all patients of PC or mixed histology [35, 36, 38, 39, 42]. These results point to a better response when radiotherapy is administered at an earlier, more active stage of disease (PC and mixed- HV-PC unicentric subtypes), rather than with the later, less metabolically active HV-subtype.
Subsequently, close follow-up and periodic surveillance are necessary to detect concurrent or ensuing malignant lesions (lymphoproliferative disease and vascular neoplasms) [44, 45] associated with CD. Notably, local recurrence has been reported as long as 11 years after complete resection.
In contrast, no effective therapy has been established for multicentric disease which is widely viewed as a systemic disease. Among very rare cases, surgery may play a limited role for cases of palliation of systemic symptoms. Steroids, single-agents, or combination chemotherapy, plus immunotherapy are currently being employed with results ranging from rare cases of complete remission, sustained manifestations of disease, to aggressive disease biology with rapidly fatal outcomes [43, 46, 47]. The worst prognosis is for patients with multicentric disease, PC-subtype, and clinical signs of neuropathy. This group appears refractory to all therapy . Long term survival may be possible in multicentric patients harboring the HV- subtype.
In this report, our patient underwent a PD for a presumed pancreatic cancer. In most cases, surgeons who treat pancreatic cancer will usually proceed to surgery without biopsy if the evidence of malignancy is strong. In this case, the initial biopsy did not demonstrate cancer. However, a study that is negative for tumor should not always be interpreted as meaning that no tumor exists. In this instance, a curable form of CD was resected. Due to the rarity of this disease, a diagnosis of CD will usually occur well after pathologic exclusion of other more common disease entities.
CD is a poorly understood disease that creates both a diagnostic and therapeutic dilemma for surgeons. Complete surgical resection of unicentric disease at the time of presentation is likely to afford the best chance for cure. Radiation therapy has been used with varied success in patients who are poor surgical candidates or in those with unresectable lesions. Long term follow-up is necessary with regard to malignant sequelae. The role of surgery in multicentric disease is limited and should not be considered a realistic treatment option. Systemic therapy in the form of steroids, single or multiple drug chemotherapies have all been used with varied success. However, there is no evidence for one approach being more consistently effective. A better understanding of the pathogenesis, natural history, and ultimately diagnosis of this disorder may lead to improvement over the current modalities available for treatment.
The authorship gratefully acknowledges the assistance of our colleagues in the Department of Gastroenterology (Ayse Aytaman MD, Gerald Fruchter, MD), and Department of Radiology (Alan M. Kantor, MD, Catherine J. Mason, MD) for their critical review of this manuscript. We also acknowledge the Armed Forces Institute of Pathology (AFIP) for their consultation of the pathology.
Written consent of patient was obtained for publication of this case report.
- Hatzitheoklitos E, Buchler MW, Friess H, Freiss H, DiSebastiano P, Poch B, Beger HG, Mohr W: Pseudolymphoma of the pancreas mimicking cancer. Pancreas. 1994, 9: 668-670. 10.1097/00006676-199409000-00020.View ArticlePubMedGoogle Scholar
- Nakashiro H, Tokunaga O, Watanabe T, Ishibashi K, Kuwaki T: Localized lymphoid hyperplasia (pseudolymphoma) of the pancreas presenting with obstructive jaundice. Hum Pathol. 1991, 22: 724-726. 10.1016/0046-8177(91)90297-3.View ArticlePubMedGoogle Scholar
- Goetze O, Banasch M, Junker K, Schmidt WE, Szymanski C: Unicentric Castleman's disease of the pancreas with massive central calcification. World J Gastroenterol. 2005, 11: 6725-6727.PubMed CentralPubMedGoogle Scholar
- Erkan N, Yildirim M, Selek E, Sayhan S: Peripancreatic Castleman disease. J Pathol. 2004, 5: 491-494.Google Scholar
- Baikovas S, Glenn D, Stanton A, Vonthethoff L, Morris DL: Castleman's disease: An unusual cause of a peripancreatic hilar mass. Aust N Z Surg. 1994, 64: 219-221.View ArticleGoogle Scholar
- Lepke RA, Pagani JJ: Pancreatic Castleman disease simulating pancreatic carcinoma on computed tomograph. J Comp Assisted Tomography. 1982, 6: 1193-1195.View ArticleGoogle Scholar
- Corbisier F, Ollier JC, Adloff M: Pancreatic localization of a Castleman's tumor. Acta Chir Belg. 1993, 93: 227-229.PubMedGoogle Scholar
- LeVan T, Clifford S, Staren ED: Castleman's tumor masquerading as a pancreatic neoplasm. Surgery. 1989, 106: 884-887.PubMedGoogle Scholar
- Le Borgne J, Joubert M, Emam N, Gaillard F, Lafergue JP, Moussu P, Lehur PA: Pancreatic localization of a Castleman's tumor. Gastroenterol Clin Biol. 1999, 23: 536-538.PubMedGoogle Scholar
- Brossard G, Ollivier S, Pellegrin JL, Barbeau P, De Mascarel A, Leng B: Pancreatic Castleman's tumor revealed by prolonged fever. Presse Med. 1992, 21: 86-PubMedGoogle Scholar
- Castleman B, Iverson L, Menendez VP: Localized Mediastinal Lymph-Node Hyperplasia Resembling Thymoma. Cancer. 1956, 9: 822-830. 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Flendrig JA: Benign giant lymphoma: clinicopathologic correlation study. The year book of cancer. Edited by: Clark RL, Cumley RW. 1970, Year Book Medical Publishers, 296-99.Google Scholar
- Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972, 29: 670-83. 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#.View ArticlePubMedGoogle Scholar
- McCarty MJ, Vukelja SJ, Banks PM, Weiss RB: Angiofollicular lymph node hyperplasia (Castleman's Disease). Cancer Treat Rev. 1995, 21: 291-310. 10.1016/0305-7372(95)90034-9.View ArticlePubMedGoogle Scholar
- Gaba AR, Stein RS, Sweet DL, Variakojis D: Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978, 69: 86-90.PubMedGoogle Scholar
- Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF: The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer. 1999, 85: 706-717. 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Kojima M, Nakamura S, Miyawaki S, Ohno Y, Sakela N, Majawa N: Progressive transformation of germinal center presenting with histologic features of hyaline-vascular type of Castleman's disease. APMIS. 2005, 113: 288-295. 10.1111/j.1600-0463.2005.apm_08.x.View ArticlePubMedGoogle Scholar
- Simko R, Nagy K, Lombay B, Kiss A, Minik K, Lukacs VH, Vamosi I: Multicentric Castleman disease and systemic lupus erythematosus phenotype in a boy with Klinefelter syndrome: long-term disease stabilization with interferon therapy. J Pediatr Hematol Oncol. 2000, 22: 180-183. 10.1097/00043426-200003000-00021.View ArticlePubMedGoogle Scholar
- Kim SR, Hayashi Y, Kang KB, Soe CG, Kim JH, Yang MK, Itoh H: A case of pseudolymphoma of the liver with chronic hepatitis. J Hepatol. 1997, 26: 209-214. 10.1016/S0168-8278(97)80028-1.View ArticlePubMedGoogle Scholar
- Hsu S-M, Waldron JA, Xie S-S, Barlogie B: Expression of interleukin-6 in Castleman's Disease. Hum Pathol. 1993, 24: 833-839. 10.1016/0046-8177(93)90132-Z.View ArticlePubMedGoogle Scholar
- Tung KSK, McCormack LJ: Angiomatous Lymphoid Hamartoma. Report of Five Cases with Review of the Literature. Cancer. 1967, 20: 525-536. 10.1002/1097-0142(1967)20:4<525::AID-CNCR2820200409>3.0.CO;2-J.View ArticlePubMedGoogle Scholar
- Lowenthal DA, Filippa DA, Richardson ME, Bertoni M, Straus DJ: Generalized Lymphadenopathy with Morphologic Features of Castleman's Disease in an HIV-Positive Man. Cancer. 1987, 60: 2454-2458. 10.1002/1097-0142(19871115)60:10<2454::AID-CNCR2820601018>3.0.CO;2-I.View ArticlePubMedGoogle Scholar
- Lachant NA, Sun Nora CJ, Leong LA, Oseas RS, Prince HE: Multicentric Angiofollicular Lymph Node Hyperplasia (Castleman's Disease) Followed by Kaposi's Sarcoma in Two Homosexual Males with Acquired Immunodeficiency Syndrome (AIDS). Am J Clin Pathol. 1985, 83: 27-33.PubMedGoogle Scholar
- Oksenhendler E, Duarte M, Soulier J, Cacoub P, Welker Y, Cadranel J, Cuzals-Hatem P, Autran B, Clauvel JP, Raphael M: Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patient. AIDS. 1996, 10: 61-67. 10.1097/00002030-199601000-00009.View ArticlePubMedGoogle Scholar
- Frizzera G: Castleman's Disease: More Questions than Answers. Hum Pathol. 1985, 156: 202-205. 10.1016/S0046-8177(85)80002-2.View ArticleGoogle Scholar
- Lotz M: Interleukin-6. Cancer Invest. 1993, 11: 732-742. 10.3109/07357909309046948.View ArticlePubMedGoogle Scholar
- Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T: Pathogenic significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease. Blood. 1989, 74: 1360-1367.PubMedGoogle Scholar
- Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D: Interleukin-6 Gene Expression in Castleman's Disease. Blood. 1991, 78: 2923-2930.PubMedGoogle Scholar
- Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW: Dysregulated Interleukin 6 Expression Produces a Syndrome Resembling Castleman's Disease in Mice. J Clin Invest. 1990, 86: 592-599.PubMed CentralView ArticlePubMedGoogle Scholar
- Frizzera G: Castleman's Disease and Related Disorders. Semin in Diagn Pathol. 1988, 5: 346-364.Google Scholar
- Yamashita Y, Hirai T, Matsukawa T, Ogata I, Takahashi M: Radiological presentations of Castleman's Diseas. Comput Med Imaging Graph. 1993, 17: 107-117. 10.1016/0895-6111(93)90052-O.View ArticlePubMedGoogle Scholar
- Tuttle RJ, Shier KJ: Angiography of angiomatous lymphoid hamartoma (Castleman Tumor) and a suggested pathogenesis. Radiology. 1979, 130: 311-315.View ArticlePubMedGoogle Scholar
- Walter JF, Rottenberg RW, Cannon WB, Sheridan LA, PIzzimenti J, Orr JT: Giant Mediastinal Lymph Node Hyperplasia (Castleman's Disease): Angiographic and Clinical Features. Am J Roentgenol. 1978, 130: 447-450.View ArticleGoogle Scholar
- Joseph N, Vogelzang RL, Hidvegi D, Neiman HL: Computed tomography of retroperitoneal castleman disease (plasma cell type) with sonographic and angiographic correlation. J Comp Assist Tomogr. 1985, 9 (3): 570-572.View ArticleGoogle Scholar
- Weisenburger DD, DeGowin RL, Gibson P, Armitage JO: Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer. 1979, 44: 457-462. 10.1002/1097-0142(197908)44:2<457::AID-CNCR2820440212>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Nordstrom DG, Tewfik HH, Latourette HB: Giant Lymph Node Hyperplasia: A Review of Literature and Report of Two Cases of Plasma Cell Variant Responding To Radiation Therapy. Int J Radiat Oncol Biol Phys. 1978, 4: 1045-1048.View ArticlePubMedGoogle Scholar
- Fitzpatrick PJ, Brown TC: Angiofollicular Lymph Node Hyperplasia. CMAJ. 1997, 99: 1259-1262.Google Scholar
- Marti S, Pahissa A, Guardia J, Moragas A, Bacardi R: Multicentric giant follicular lymph node hyperplasia: A favorable response to radiotherapy. Cancer. 1983, 51: 808-810. 10.1002/1097-0142(19830301)51:5<808::AID-CNCR2820510510>3.0.CO;2-5.View ArticlePubMedGoogle Scholar
- Stokes SH, Griffith RC, Thomas PRM: Agiofollicular lymph node hyperplasia (Castleman's Disease) associated with vertebral destruction. Cancer. 1985, 56: 876-879. 10.1002/1097-0142(19850815)56:4<876::AID-CNCR2820560429>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
- Sethi T, Joshi K, Sharma SC, Gupta BD: Radiation therapy in the management of giant lymph node hyperplasia. Br J Radiol. 1990, 63: 648-650.View ArticlePubMedGoogle Scholar
- Massey GV, Kornstein MJ, Wahl D, Huang XL, McCrady CW, Carchman RA: Angiofollicular Lymph Node Hyperplasia (Castleman's Disease) in an Adolescent Female: Clinical and Immunologic Findings. Cancer. 1991, 68: 1365-1372. 10.1002/1097-0142(19910915)68:6<1365::AID-CNCR2820680630>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
- Veldhuis GJ, van der Leest AHD, de Wolf JTM, de Vries EGE, Vellenga E: A case of localized Castleman's Disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol. 1996, 73: 47-50. 10.1007/s002770050201.View ArticlePubMedGoogle Scholar
- Beck JT, Hsu S-M, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B: Brief Report: Alleviation of systemic manifestations of Castleman's Disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994, 330: 602-605. 10.1056/NEJM199403033300904.View ArticlePubMedGoogle Scholar
- Vasef M, Katzin WE, Mendelsohn G, Reydman M: Report of a case of localized Castleman's Disease with progression to malignant lymphoma. Am J Clin Pathol. 1992, 98: 633-636.PubMedGoogle Scholar
- Gerald W, Kostianovsky M, Rosai J: Development of vascular neoplasia in Castleman's Disease. Report of seven cases. Am J Surg Pathol. 1990, 14: 603-614.View ArticlePubMedGoogle Scholar
- Frizzera G, Peterson BA, Bayrd ED, Goldman A: A Systemic Lymphoproliferative Disorder with Morphologic Features of Castleman's Disease: Clinical Findings and Clinicopathologic Correlations in 15 Patients. J Clin Oncol. 1985, 3: 1202-1216.PubMedGoogle Scholar
- Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H: Multicentric Angiofollicular Lymph Node Hyperplasia: A Clinicopathologic Study of 16 Cases. Hum Pathol. 1985, 16: 162-172. 10.1016/S0046-8177(85)80065-4.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.